About Enhancer
| Enhancer ID: | E_02_0454 |
| Species: | human |
| Position : | chr8:18388409-18390409   |
| Biosample name: | |
| Experiment class : | High+Lowthroughput |
| Enhancer type: | Enhancer |
| Disease: | Cancer, type 2 diabetes |
| Pubmed ID: | 30149019 |
| Enhancer experiment: | Statistical analysis, PCR |
| Enhancer experiment description: | Genetic polymorphisms of NAT2 modify drug efficacy and toxicity and susceptibility to diseases such as cancer and type 2 diabetes. The N-acetylation capacity of NAT2 in the presence of SIRT1 enhancer was significantly decreased (p<0.001), conversely, the transient silencing of SIRT1 resulted in an increase of N-acetylation capacity (p<0.001). |
About Target gene
| Target gene : | NAT2,SIRT1 |
| Strong evidence: | qRT-PCR,qPCR,ChIP,3C |
| Less strong evidence: | RNA-Seq |
| Target gene experiment description: | Genetic polymorphisms of NAT2 modify drug efficacy and toxicity and susceptibility to diseases such as cancer and type 2 diabetes. The N-acetylation capacity of NAT2 in the presence of SIRT1 enhancer was significantly decreased (p<0.001), conversely, the transient silencing of SIRT1 resulted in an increase of N-acetylation capacity (p<0.001). ;Genetic polymorphisms of NAT2 modify drug efficacy and toxicity and susceptibility to diseases such as cancer and type 2 diabetes. The N-acetylation capacity of NAT2 in the presence of SIRT1 enhancer was significantly decreased (p<0.001), conversely, the transient silencing of SIRT1 resulted in an increase of N-acetylation capacity (p<0.001). |
About TF
| TF name : | -- |
| TF experiment: | ????,PCR |
| TF experiment description: | Genetic polymorphisms of NAT2 modify drug efficacy and toxicity and susceptibility to diseases such as cancer and type 2 diabetes. The N-acetylation capacity of NAT2 in the presence of SIRT1 enhancer was significantly decreased (p<0.001), conversely, the transient silencing of SIRT1 resulted in an increase of N-acetylation capacity (p<0.001). ;Genetic polymorphisms of NAT2 modify drug efficacy and toxicity and susceptibility to diseases such as cancer and type 2 diabetes. The N-acetylation capacity of NAT2 in the presence of SIRT1 enhancer was significantly decreased (p<0.001), conversely, the transient silencing of SIRT1 resulted in an increase of N-acetylation capacity (p<0.001). |
About Function
| Enhancer function : | Genetic polymorphisms of NAT2 modify drug efficacy and toxicity and susceptibility to diseases such as cancer and type 2 diabetes. The N-acetylation capacity of NAT2 in the presence of SIRT1 enhancer was significantly decreased (p<0.001), conversely, the transient silencing of SIRT1 resulted in an increase of N-acetylation capacity (p<0.001). |
| Enhancer function experiment: | Immunohistochemical staining |
| Enhancer function experiment description: |
Genetic polymorphisms of NAT2 modify drug efficacy and toxicity and susceptibility to diseases such as cancer and type 2 diabetes. The N-acetylation capacity of NAT2 in the presence of SIRT1 enhancer was significantly decreased (p<0.001), conversely, the transient silencing of SIRT1 resulted in an increase of N-acetylation capacity (p<0.001). |
About SNP
Upstream Pathway Annotation of TF
| GeneName | Pathway Name | Source | Gene Number |
|---|
Enhancer associated network
The number on yellow line represents the distance between enhancer and
target gene